Wang Hua, Schabath Matthew B, Liu Ying, Han Ying, Li Qi, Gillies Robert J, Ye Zhaoxiang
Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Eur J Radiol. 2016 Nov;85(11):1934-1940. doi: 10.1016/j.ejrad.2016.08.023. Epub 2016 Aug 30.
To determine if clinical and CT characteristics of surgically resected lung adenocarcinomas can distinguish those harboring ALK rearrangements from EGFR mutations.
Patients who had surgical resection and histologically confirmed lung adenocarcinoma were enrolled, including 41 patients with ALK rearrangements and 66 patients with EGFR mutations. Eighteen categorical and six quantitative CT characteristics were used to evaluate the tumors. Differences in clinical and CT characteristics between the two groups were investigated.
Age (P=0.003), histological subtypes (P<0.001), pathological stage (P=0.007), and five CT characteristics, including size (P<0.001), GGO (P=0.001), bubble-like lucency (P=0.048), lymphadenopathy (P=0.001), and tumor shadow disappearance rate (P=0.005) were significantly different between patients harboring ALK rearrangements compared to patients with EGFR mutations. When we compared histologic components, a solid pattern was more common (P=0.009) in tumors with ALK rearrangements, and lepidic and acinar patterns were more common (P<0.001 and P=0.040, respectively) in those with EGFR mutations. Backward elimination analyses revealed that age (OR=0.93; 95% CI 0.89-0.98), GGO (OR=0.14; 95% CI 0.03-0.67), and lymphadenopathy (OR=4.15; 95% CI 1.49-11.60) were significantly associated with ALK rearrangement status.
Our analyses revealed that clinical and CT characteristics of lung adenocarcinomas harboring ALK rearrangements were significantly different, compared with those with EGFR mutations. These differences may be related to the molecular pathology of these diseases.
确定手术切除的肺腺癌的临床和CT特征能否区分携带ALK重排的肿瘤与EGFR突变的肿瘤。
纳入接受手术切除且经组织学确诊为肺腺癌的患者,其中包括41例携带ALK重排的患者和66例携带EGFR突变的患者。采用18项分类CT特征和6项定量CT特征对肿瘤进行评估。研究两组患者临床和CT特征的差异。
携带ALK重排的患者与携带EGFR突变的患者相比,年龄(P=0.003)、组织学亚型(P<0.001)、病理分期(P=0.007)以及5项CT特征存在显著差异,这5项CT特征包括大小(P<0.001)、磨玻璃影(GGO,P=0.001)、泡状透亮影(P=0.048)、淋巴结病(P=0.001)和肿瘤阴影消失率(P=0.005)。在比较组织学成分时,实性模式在携带ALK重排的肿瘤中更为常见(P=0.009),而鳞屑样和腺泡样模式在携带EGFR突变的肿瘤中更为常见(分别为P<0.001和P=0.040)。向后逐步回归分析显示,年龄(OR=0.93;95%CI 0.89-0.98)、磨玻璃影(OR=0.14;95%CI 0.03-0.67)和淋巴结病(OR=4.15;95%CI 1.49-11.60)与ALK重排状态显著相关。
我们的分析显示,与携带EGFR突变的肺腺癌相比,携带ALK重排的肺腺癌的临床和CT特征存在显著差异。这些差异可能与这些疾病的分子病理学有关。